苯巴那酯（cenobamate）美国获批治疗成人局灶性癫痫

Cenobamate is a sodium ion channel blocker that is thought to reduce the repetitive release of electrical impulses from nerve cells by inhibiting voltage-gated sodium currents and positively regulating GABAA (γ-aminobutyric acid) receptor activity through isomerism. Approved by the US FDA for the treatment of focal epilepsy in adults.

The safety and efficacy of cenobamate were tested in two randomized, double-blind, placebo-controlled clinical studies involving 655 adult patients. In clinical trials, patients were treated with varying doses of cenobamate or a placebo.

The trial results showed that compared with the baseline level, different doses of cenobamate reduced the frequency of epilepsy in patients to: 36% (100mg), 55% (200mg), 55% (400mg), respectively. This value was 24% in the placebo group. It can be seen that cenobamate can reduce the frequency of epilepsy, relieve the pain of patients, have a positive effect on the patient's condition, and has a significant therapeutic effect.

Treatment with cenobamate may cause vision changes, including double vision, blurred vision, and visual impairment. And the drug has drowsiness and sedative effects. Therefore, patients should try to avoid doing work that requires a high degree of concentration and operating or driving machinery when receiving this drug.

The above is the introduction about cenobamate. If patients have other questions about this drug (such as drug price, purchasing channels, precautions, usage, etc.), they can consult the medical companion travel service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: